Endoscopic Submucosal Tunnel Dissection for Upper Gastrointestinal Submucosal Tumors Originating from the Muscularis Propria Layer: A Single-Center Study

Xiaowei Tang, Yutang Ren, Silin Huang, Qiaoping Gao, Jieqiong Zhou, Zhengjie Wei, Bo Jiang, and Wei Gong

Department of Gastroenterology, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou, Department of Gastroenterology, Beijing Tsinghua Changgung Hospital Medical Center, Tsinghua University, Beijing, and Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China

Background/Aims: In recent years, endoscopic submucosal tunnel dissection (ESTD) has gained popularity worldwide. The aim of this study was to evaluate the safety and efficacy of ESTD in treating upper gastrointestinal submucosal tumors (SMTs) in a large-volume endoscopic center.

Methods: Patients with SMTs were enrolled in this study between January 2012 and January 2015. Demographic data, clinical data, and treatment outcome were collected and analyzed.

Results: Seventy SMTs originating from the muscularis propria (MP) layer were identified in 69 patients. All patients successfully underwent the ESTD procedure. The mean procedure time was 49.0±29.5 minutes, and the mean tumor size was 18.7±7.2 mm. Among all lesions, the majority (70.0%) were located in the esophagus, 12.9% in the cardia, and 17.1% in the stomach. Complete resection was achieved in 67 lesions (95.7%). Perforation occurred in three patients (4.3%), who were treated by endoclips. Pneumothorax occurred in two patients (2.9%) and was successfully managed by thoracic drainage. During a median follow-up of 18.1 months, patients were free of local recurrence or distant metastasis.

Conclusions: Our results demonstrated the feasibility and safety of ESTD in treating upper gastrointestinal SMTs originating from the MP layer. Large-scale comparative studies with other treatment methods should be conducted in the future.

Key Words: Endoscopic submucosal tunnel dissection; Submucosal tumor; Upper gastrointestinal; Treatment outcome

INTRODUCTION

Gastrointestinal (GI) submucosal tumors (SMTs) are not rare, and with increasing use of esophagogastroduodenoscopy and improvement of diagnostic modalities, they are estimated to increase. Gastrointestinal stromal tumor (GISTs) are the most common among SMTs of the stomach, which usually considered to the candidate for resection. Nowadays, laparoscopic or open surgery, endoscopic submucosal dissection (ESD), and endoscopic full-thickness resection (EFR) with or without laparoscopic assistance, were reported to resect SMTs worldwide. However, these above treatments have some limitations. Surgical approaches are more invasive and often require longer hospital stay. ESD and EFR have the complication of perforation, which may be difficult to close and even require surgery.

In 2010, Inoue et al. reported peroral endoscopic myotomy (POEM) for treating achalasia, in which a submucosal tunnel is created to provide working space for cutting the circular muscle layer to treat achalasia. Driven by the innovation, we successfully utilized a similar technique, endoscopic submucosal tunnel dissection (ESTD) for the management of esophageal and gastric SMTs. Since then, we continued to use this technique in our clinical practice, and also tried to employ this novel endoscopic method to manage other lesions in the stomach. Therefore, we aimed to examine the safety and efficacy of ESTD in upper GI SMTs in this study.
MATERIALS AND METHODS

1. Patients

Between January 2012 and January 2015, 69 patients, with upper GI SMTs originating from the muscularis propria (MP) identified by upper endoscopy and endoscopic ultrasonography (EUS) were treated by ESTD at Department of Gastroenterology, Nanfang Hospital, Southern Medical University, China. Indication for ESTD procedure were as follows: (1) the tumor was 1 to 4 cm in diameter; (2) EUS examination showed that the tumor originated from the MP layer; (3) the patient could tolerate anesthesia with tracheal intubation; and (4) the patient consented to ESTD in our center. The data were prospectively collected and retrospectively reviewed. All patients were informed of a detailed explanation of the treatment and complications of the procedure, and the possibility of additional surgery because of complications or pathological diagnosis of resected specimens. Informed patient consent was obtained before the ESTD procedures. This study was approved by the ethics committee of the Nanfang Hospital, Southern Medical University (Guangzhou, China).

Fig. 1. Case illustration of endoscopic submucosal tunnel dissection for esophageal submucosal tumors (SMTs). (A) SMT located at the posterior wall of the mid-esophagus. (B) Endoscopic ultrasonography revealed an 18.7×11.2 mm hypoechoic submucosal lesion. (C, D) A 2-cm longitudinal mucosal incision was made approximately 4 cm proximal to SMT; submucosal dissection was performed, creating a submucosal tunnel until the tumor was visible. (E) Dissection was performed along the margin of the tumor. (F) Endoscopic view of the submucosal tunnel after removal of the tumor. (G) Endoclips were used to close the entry of the submucosal tunnel. (H, I) Pathological examination revealed that the resected specimen was a 15-mm leiomyoma, and positive staining (H&E stain, ×20) with vimentin was observed on the upper right side.
2. Endoscopic equipment and procedures

A forward-viewing endoscope (GIFQ240Z; Olympus, Tokyo, Japan) was attached with a transparent distal cap (MH-588; Olympus). A hook knife (KD-620L; Olympus) or a hybrid knife (Erbe, Tübingen, Germany) was used to dissect both the submucosal layer and the tumors. A coagulating forceps (Coagrasper, FD-410L; Olympus) was used for hemostasis. A carbon dioxide (CO\(_2\)) insufflator (UCR; Olympus) was used during all the procedure. VIO 200 D electrogenerator (Erbe) was used for electrosurgery. Hemostatic clips (EZ-CLIP, HX-110QR, Olympus; or Resolution, M00522610, Boston Scientific, Boston, MA, USA) were applied for closing the tunnel entry. All the ESTD procedures were performed by a single operator (W.G.).

The procedures were performed with the patients under general anesthesia with endotracheal intubation. CO\(_2\) insufflation was used during the procedure. The standard steps of the procedure were described previously (also see Figs 1-3).\(^8\)

1) Creation of the submucosal tunnel

The mixed solution of 10 mL saline with 0.3\% indigo carmine and 1:100,000 epinephrine was injected 4 to 5 cm proximal to

---

Fig. 2. Case illustration of endoscopic submucosal tunnel dissection for the cardiac submucosal tumor (SMT). (A) SMT located at the cardia. (B) Endoscopic ultrasonography revealed a 21.9×15.9 mm hypoechoic submucosal lesion. (C, D) A 2-cm longitudinal mucosal incision was made in the esophagus approximately 4 cm proximal to the SMT; submucosal dissection was performed, creating a submucosal tunnel until the tumor was visible. (E) Dissection was performed along the margin of the tumor. (F) Endoscopic view of the submucosal tunnel after removal of the tumor. (G) Endoclips were used to close the entry to the submucosal tunnel. (H, I) Pathological examination showed that the resected specimen was a 25-mm gastrointestinal stromal tumor, and positive staining (H&E stain, ×20) with CD34 was observed on the upper right side.
the SMTs, until the mucosa was fully lifted. A 2-cm longitudinal mucosal incision was made on the mucosal layer, creating an entry to the submucosal layer. Then a submucosal tunnel was created downwards with ESD until the tumor was exposed.

2) Dissection of the SMTs
Dissection was performed along the margin of the tumor with a hook knife or a hybrid knife. The tumor was then removed and the visible vessels and bleeding area in the tunnel were carefully coagulated.

3) Closure of mucosal entry
The mucosal entry site, usually 2-cm long, was closed with hemostatic clips. During the procedure, endoscopic hemostasis was performed with the knife itself or with a hemostatic forceps when active bleeding was noticed. After completion of procedure, preventive coagulation was routinely performed for all visible vessels on the submucosal tunnel using hemostatic forceps or argon plasma coagulation.

3. Postprocedure management
Patients were fasted from food and water for 48 hours, being
given parenteral nutrition instead. Proton pump inhibitors and antibiotics were routinely used for 3 days. The common complications of ESTD include pneumothorax, perforation and bleeding. Pneumothorax was suspected when decreasing of oxygen saturation occurred, and confirmed by chest X-ray or computed tomogram (CT). Perforation was defined as tunnel mucosa perforation, and recognized endoscopically or by presence of free air on abdominal plain radiograph or CT. Bleeding was defined as an oozing or spurring bleeding observed and requiring the use of coagulating forceps or endoclips.

4. Histopathological evaluation

Resected specimens were retrieved and immediately fixed in a 10% buffered formalin solution. Hematoxylin and eosin staining was followed by immunohistochemical staining (CD34, CD117, actin, S-100, desmin, vimentin, and Ki-67) for differential diagnosis. “En bloc resection” was defined as a tumor removed in a single piece. “Complete resection” was defined as a tumor removed as a single piece and the capsule of the tumor was intact. 

5. Follow-up

All patients were scheduled to take a follow-up visit at 3, 6 months and 1 year after ESTD for upper endoscopy and EUS. If there is no residual tumor, follow-up is performed annually.

6. Statistical analysis

Data were collected and analyzed by means of descriptive statistics (mean, standard deviation, or median, and range). Frequencies and percentages were calculated for categorical variables. All data were analyzed using SPSS version 18.0 (SPSS Inc., Chicago, II, USA).

Table 1. Baseline Characteristics of Patients

| Variable               | Value                  |
|------------------------|------------------------|
| No. of patients        | 69                     |
| Age, yr                | 48.0±11.2 (19–69)      |
| Sex, female/male       | 24/45                  |
| Presenting symptoms    |                        |
| Asymptomatic           | 52 (75.4)              |
| Epigastric discomfort  | 7 (10.1)               |
| Chest discomfort        | 5 (7.2)                |
| Dysphagia              | 3 (4.3)                |
| Regurgitation          | 2 (2.9)                |
| Tumor location         |                        |
| Esophagus              | 49 (70.0)              |
| Cardia                 | 9 (12.9)               |
| Stomach                | 12 (17.1)              |

Data are presented as mean±SD (range) or number (%). The sum total of lesions is 70 since a patient has two lesions.

RESULTS

1. Baseline characteristics of patients

The baseline characteristics of patients were shown in Table 1. Seventy SMTs lesions in 69 patients were removed by ESTD. Mean age of the patients was 48.0±11.2 years (range, 19 to 69 years), and female-to-male ratio was 24:45. Fifty-two patients (75.4%) were asymptomatic and their tumors were discovered incidentally during routine physical examination. The most common presenting symptom that patients reported was epigastric discomfort (n=7, 10.1%). Of all the lesions, 49 (70.0%) were located in the esophagus, nine (12.9%) in the cardia and 12 (17.1%) in the stomach.

Table 2. Clinicopathologic Outcome of Endoscopic Submucosal Tunnel Dissection for Patients with Submucosal Tumors

| Variable                     | Overall                                      |
|------------------------------|----------------------------------------------|
| Operation time, min          | 49.0±29.5 (30–150)                           |
| Insufflation                 |                                              |
| Air                          | 4 (5.8)                                     |
| CO₂                          | 65 (94.2)                                   |
| Tumor size, mm               | 18.7±7.2 (10–40)                            |
| No. of tumors based on size  |                                              |
| ≤20 mm                       | 53 (75.7)                                   |
| >20 mm                       | 17 (24.3)                                   |
| En bloc resection            | 67 (95.7)                                   |
| Complete resection           | 67 (95.7)                                   |
| Complication                 |                                              |
| Perforation                  | 3 (4.3)                                     |
| Pneumothorax                 | 2 (2.9)                                     |
| Subcutaneous emphysema       | 4 (5.8)                                     |
| Pneumoperitoneum             | 1 (1.4)                                     |
| Delayed bleeding             | 0                                            |
| Pathologic diagnosis         |                                              |
| Leiomyoma                    | 59 (84.3)                                   |
| Esophagus                    | 49/59 (83.1)                                |
| Cardia                       | 7/59 (11.9)                                 |
| Gastric antrum               | 3/59 (5.0)                                  |
| Gastrointestinal stromal tumor | 11 (15.7)       |
| Cardia                       | 2/11 (18.2)                                 |
| Gastric fundus               | 6/11 (54.5)                                 |
| Gastric antrum               | 3/11 (27.3)                                 |
| Hospital stay, day           | 5.8±1.5 (3–10)                              |
| Follow-up time, mo           | 18.1 (6–35)                                 |
| Recurrence rate, %           | 0                                            |

Data are presented as mean±SD (range), number (%), or median (range). The sum total of lesions is 70 since a patient has two lesions.
2. Clinical outcomes of ETSD

ESTD was performed successfully in all cases. No one was converted to laparoscopy or thoracoscopy. All SMTs originated from the MP layer. As shown in Table 2, the average lesion size was 18.7 ± 7.2 mm (range, 10 to 40 mm). The mean required time for the procedure was 49.0 ± 29.5 minutes (range, 30 to 150 minutes). In the early period (before June 2012), the air insufflation was used in four cases during the procedure. Then, CO₂ insufflation was applied in the remaining cases (n=65). All tumors were resected successfully, with an en bloc and complete resection rate of 95.7% (67 of 70 lesions), respectively. Three esophageal tumors were resected in several pieces owing to larger size (40 mm). Three perforations were recognized during the procedure and were successfully treated by endoscopic clipping. No delayed perforation occurred in all the patients. Two patients experienced subcutaneous emphysema and a decreasing of oxygen saturation during the procedure. X-ray examination verified the occurrence of pneumothorax in them. Both of patients were treated with thoracic drainage, and they recovered satisfactorily after chest tube placement for 1 week. Sole subcutaneous emphysema occurred in two patients, and disappeared spontaneously after procedure. One patient developed pneumoperitoneum, which were resolved spontaneously without special treatment. No other intraoperative and immediate postoperative complications, including delayed bleeding and infections occurred. The mean length of the hospital stay was 5.8 ± 1.5 days (range, 3 to 10 days).

3. Histopathological examination and follow-up

Histopathological examination identified 59 cases of leiomyoma (84.3%) and 11 cases of GIST (15.7%). According to pathological results, 49 leiomyoma (49/59, 83.1%) located in the esophagus, seven (7/59, 11.9%) in the cardia, and three (3/59, 5.0%) in the gastric antrum; with regard to GIST, two (2/11, 18.2%) in the cardia, six (6/11, 54.5%) in the fundus, and three (3/11, 27.3%) in the antrum. Based on the mitotic index (less than five mitotic figures noted per 50 high-power fields), the 11 GISTs were low-risk. During a median follow-up of 18.1 months (range, 6 to 35 months), there was no recurrence or distant metastasis, and no postprocedure leakages or other major complications occurred.

DISCUSSION

For the treatment of upper GI SMTs, laparoscopic or open surgery is usually regarded as the standard approach; however, with the development of ESD, endoscopic resection also become available and is regarded recently as minimally invasive resection methods for smaller lesions. Although ESD and EFR have come to be regarded recently as minimally invasive resection methods for SMTs, they can be associated with the major complication of perforations; otherwise these can be difficult to close sometimes and may require resort to surgery. The emerging endoscopic method, ESTD has been proved to be safe and effective for treating upper GI SMTs in several pilot studies.8,9,11-14

Three years ago, we published our preliminary results of ESTD for treating esophageal and cardiac SMTs.8 After that, we continued to use this novel technique for the management of upper GI SMTs. In this study, we enrolled 69 cases of patients with 70 SMTs, all of whom underwent the treatment of ESTD. We found that ESTD not only was feasible and effective for SMTs in the esophagus and cardia, but also in the stomach. All tumors were resected successfully, the mean procedural time was 49.0 minutes, which was comparable to other studies (range, 40 to 78.3 minutes).12-15 Due to the large size (40 mm), three esophageal tumors were piecemeal resected. There may be a concern whether piecemeal resection could result into the recurrence of tumor. However, no tumor, including the piecemeal resected ones, occurred recurrence during the follow-up period.

Among our cases, 12 SMTs located in the stomach, including six in the fundus and six in the antrum. Due to the large lumen, relatively high instability and thicker mucosa, it would be more difficult to create submucosal tunnel in the stomach than esophagus. So at early period of the study, we only included patients with SMTs in the esophagus or the cardia. After gaining enough operational experience of ESTD for esophageal SMTs, we then began to perform gastric ESTD. According to our experience, it is relatively easier to perform ESTD in the gastric fundus adjacent to cardia, the lesser curvature of gastric body, and the greater curvature of gastric body and antrum than the others. As for the SMTs located in the gastric fundus near to cardia, we used trans-cardiac submucosal tunneling way to resect the tumor. This method has two advantages: for one thing, it is performed in a direct vision, so it can avoid retroflexion of endoscope; for another, the mucosal incision was made in the esophagus, which can prevent the erosion or pollution of gastric juice. Due to the thickness of the gastric mucosa, infolding of the mucosa at the resection site easily occurs. Some authors recommended using balloon dilatation to reveres the folding of the mucosa and facilitate incision closure.16 We also met such a problem during procedure in some cases, but it can be solved by repeated insufflation and suction in the stomach. By using this method, the gastric mucosa became unfolded and incision site was closed successfully.

We also encountered two SMTs in one patient. Both of them located in the esophagus, and were resected simultaneously in one procedure. No complication occurred in this patient. Other authors also described the feasibility of ESTD for GI multiple SMTs. Chen et al.17 succeeded to resect two separate esophageal and cardia SMTs under the same submucosal tunnel. Zhang et al.18 expanded this experience, and applied ESTD for treating 23 patients with 49 multiple SMTs from MP layer in upper GI tract. They reported that all the SMTs were resected completely by
CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

We acknowledge the support of grants from the National Natural Science Foundation of China (number: 81101610), Scientific Research Projects of Guangdong Province (number: 2013B021800311) and Medical Research Foundation of Guangdong Province (number: WSTJJ2011110142092192119760913465X).

REFERENCES

1. Goto O, Uraoka T, Horii J, Yahagi N. Expanding indications for ESD: submucosal disease (SMT/carcinoid tumors). Gastrointest Endosc Clin N Am 2014;24:169-181.

2. von Rahden BH, Stein HJ, Feussner H, Siewert JR. Enucleation of submucosal tumors of the esophagus: minimally invasive versus open approach. Surg Endosc 2004;18:924-930.

3. Lee IL, Lin PY, Tung SY, Shen CH, Wei KL, Wu CS. Endoscopic submucosal dissection for the treatment of intraluminal gastric subepithelial tumors originating from the muscularis propria layer. Endoscopy 2006;38:1024-1028.

4. Shi Q, Zhong YS, Yao LQ, Zhou PH, Xu MD, Wang P. Endoscopic submucosal dissection for treatment of esophageal submucosal tumors originating from the muscularis propria layer. Gastrointest Endosc 2011;74:1194-1200.

5. Hiki N, Yamamoto Y, Fukunaga T, et al. Laparoscopic and endoscopic cooperative surgery for gastrointestinal stromal tumor dissection. Surg Endosc 2008;22:1729-1735.

6. Schlag C, Wilhelm D, von Delius S, Feussner H, Meining A. EndoResect study: endoscopic full-thickness resection of gastric subepithelial tumors. Endoscopy 2013;45:4-11.

7. Inoue H, Minami H, Kobayashi Y, et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 2010;42:265-271.

8. Gong W, Xiong Y, Zhi F, Liu S, Wang A, Jiang B. Preliminary experience of endoscopic submucosal tunnel dissection for upper gastrointestinal submucosal tumors. Endoscopy 2012;44:231-235.

9. Wang H, Tan Y, Zhou Y, et al. Submucosal tunneling endoscopic resection for upper gastrointestinal submucosal tumors originating from the muscularis propria layer. Eur J Gastroenterol Hepatol 2015;27:776-780.

10. Li QL, Yao LQ, Zhou PH, et al. Submucosal tumors of the esophago-gastric junction originating from the muscularis propria layer: a large study of endoscopic submucosal dissection (with video). Gastrointest Endosc 2012;75:1153-1158.

11. Inoue H, Ikeda H, Hosoya T, et al. Submucosal endoscopic tumor resection for subepithelial tumors in the esophagus and cardia.
12. Xu MD, Cai MY, Zhou PH, et al. Submucosal tunneling endoscopic resection: a new technique for treating upper GI submucosal tumors originating from the muscularis propria layer (with videos). Gastrointest Endosc 2012;75:195-199.

13. Ye LP, Zhang Y, Mao XL, Zhu LH, Zhou X, Chen JY. Submucosal tunneling endoscopic resection for upper gastrointestinal subepithelial tumors originating from the muscularis propria layer. Gastrointest Endosc 2012;75:195-199.

14. Liu BR, Song JT, Kong LJ, Pei FH, Wang XH, Du YJ. Tunneling endoscopic muscularis dissection for subepithelial tumors originating from the muscularis propria of the esophagus and gastric cardia. Surg Endosc 2013;27:4354-4359.

15. Zhang C, Hu JW, Chen T, et al. Submucosal tunneling endoscopic resection for upper gastrointestinal multiple submucosal tumors originating from the muscular propria layer: a feasibility study. Indian J Cancer 2015;51 Suppl 2:e52-e55.

16. Li QL, Chen WF, Zhang C, et al. Clinical impact of submucosal tunneling endoscopic resection for the treatment of gastric submucosal tumors originating from the muscularis propria layer (with video). Surg Endosc 2015;29:3640-3646.

17. Chen H, Xu Z, Huo J, Liu D. Submucosal tunneling endoscopic resection for simultaneous esophageal and cardia submucosal tumors originating from the muscularis propria layer (with video). Dig Endosc 2015;27:155-158.

18. Yasumasa K, Nakajima K, Endo S, Ito T, Matsuda H, Nishida T. Carbon dioxide insufflation attenuates parietal blood flow obstruction in distended colon: potential advantages of carbon dioxide insufflated colonoscopy. Surg Endosc 2006;20:587-594.

19. Stavropoulos SN, Desilets DJ, Fuchs KH, et al. Per-oral endoscopic myotomy white paper summary. Surg Endosc 2014;28:2005-2019.

20. Chun SY, Kim KO, Park DS, et al. Endoscopic submucosal dissection as a treatment for gastric subepithelial tumors that originate from the muscularis propria layer: a preliminary analysis of appropriate indications. Surg Endosc 2013;27:3271-3279.

21. Catalano F, Rodella L, Lombardo F, et al. Endoscopic submucosal dissection in the treatment of gastric submucosal tumors: results from a retrospective cohort study. Gastric Cancer 2013;16:563-570.